BACE1 influences clinical manifestations and central inflammation in relapsing remitting multiple sclerosis.

[1]  N. Ginestet,et al.  CSF β-amyloid is not a prognostic marker in multiple sclerosis patients. , 2022, Multiple sclerosis and related disorders.

[2]  U. Dianzani,et al.  Cerebrospinal fluid biomarkers and cognitive functions at multiple sclerosis diagnosis , 2022, Journal of Neurology.

[3]  Yaohua Hu,et al.  Reduction BACE1 expression via suppressing NF-κB mediated signaling by Tamibarotene in a mouse model of Alzheimer’s disease , 2021, IBRO neuroscience reports.

[4]  B. Hosten,et al.  STAT3 inhibition protects against neuroinflammation and BACE1 upregulation induced by systemic inflammation. , 2020, Immunology letters.

[5]  A. Grimm,et al.  Insights into Disease-Associated Tau Impact on Mitochondria , 2020, International journal of molecular sciences.

[6]  K. Blennow,et al.  CSF levels of the BACE1 substrate NRG1 correlate with cognition in Alzheimer’s disease , 2020, Alzheimer's Research & Therapy.

[7]  B. de Strooper,et al.  The β-Secretase BACE1 in Alzheimer’s Disease , 2020, Biological Psychiatry.

[8]  D. Galimberti,et al.  Low CSF β-amyloid levels predict early regional grey matter atrophy in multiple sclerosis. , 2019, Multiple sclerosis and related disorders.

[9]  J. Hillert,et al.  Disability worsening among persons with multiple sclerosis and depression , 2019, Neurology.

[10]  Jian-mei Gao,et al.  Icariside II inhibits lipopolysaccharide-induced inflammation and amyloid production in rat astrocytes by regulating IKK/IκB/NF-κB/BACE1 signaling pathway , 2019, Acta Pharmacologica Sinica.

[11]  W. Hawse,et al.  The Alzheimer’s Disease–Associated Protein BACE1 Modulates T Cell Activation and Th17 Function , 2019, The Journal of Immunology.

[12]  Gerard Ill-Raga,et al.  BACE1 Translation: At the Crossroads Between Alzheimer’s Disease Neurodegeneration and Memory Consolidation , 2019, Journal of Alzheimer's disease reports.

[13]  J. Graves,et al.  Mitochondrial Dysfunction and Multiple Sclerosis , 2019, Biology.

[14]  S. Capellari,et al.  Antemortem CSF Aβ42/Aβ40 ratio predicts Alzheimer's disease pathology better than Aβ42 in rapidly progressive dementias , 2018, Annals of clinical and translational neurology.

[15]  J. DeLuca,et al.  Recommendations for cognitive screening and management in multiple sclerosis care , 2018, Multiple sclerosis.

[16]  M. Stecker,et al.  Amyloid toxicity in Alzheimer’s disease , 2018, Reviews in the neurosciences.

[17]  M. Bozzali,et al.  CSF β-amyloid predicts prognosis in patients with multiple sclerosis , 2018, Multiple sclerosis.

[18]  D. Centonze,et al.  Amyloid-β Homeostasis Bridges Inflammation, Synaptic Plasticity Deficits and Cognitive Dysfunction in Multiple Sclerosis , 2017, Front. Mol. Neurosci..

[19]  Nicholas C. Firth,et al.  Progression of regional grey matter atrophy in multiple sclerosis , 2017, bioRxiv.

[20]  M. Filippi,et al.  Gray matter trophism, cognitive impairment, and depression in patients with multiple sclerosis , 2017, Multiple sclerosis.

[21]  L. Shaw,et al.  BACE1 Dynamics Upon Inhibition with a BACE Inhibitor and Correlation to Downstream Alzheimer’s Disease Markers in Elderly Healthy Participants , 2017, Journal of Alzheimer's disease : JAD.

[22]  A. Kurne,et al.  The association of cognitive impairment with gray matter atrophy and cortical lesion load in clinically isolated syndrome. , 2016, Multiple sclerosis and related disorders.

[23]  D. Centonze,et al.  Cerebrospinal fluid lactate is associated with multiple sclerosis disease progression , 2016, Journal of Neuroinflammation.

[24]  J. Findlay,et al.  BACE1 activity impairs neuronal glucose oxidation: rescue by beta-hydroxybutyrate and lipoic acid , 2015, Front. Cell. Neurosci..

[25]  Y. Qian,et al.  IL-17A is implicated in lipopolysaccharide-induced neuroinflammation and cognitive impairment in aged rats via microglial activation , 2015, Journal of Neuroinflammation.

[26]  C Montomoli,et al.  BREMSO: a simple score to predict early the natural course of multiple sclerosis , 2015, European journal of neurology.

[27]  R. Vassar,et al.  The contribution of activated astrocytes to Aβ production: Implications for Alzheimer's disease pathogenesis , 2011, Journal of Neuroinflammation.

[28]  D. Centonze,et al.  Cognitive and Cortical Plasticity Deficits Correlate with Altered Amyloid-β CSF Levels in Multiple Sclerosis , 2011, Neuropsychopharmacology.

[29]  K. Blennow,et al.  Reduced cerebrospinal fluid BACE1 activity in multiple sclerosis , 2009, Multiple sclerosis.

[30]  R. Vassar,et al.  Molecular Neurodegeneration BioMed Central Review The Alzheimer's disease β-secretase enzyme, BACE1 , 2007 .

[31]  Stefan J. Teipel,et al.  Levels of β-Secretase (BACE1) in Cerebrospinal Fluid as a Predictor of Risk in Mild Cognitive Impairment , 2007 .

[32]  B. de Strooper,et al.  Regulated Intramembrane Proteolysis of the Interleukin-1 Receptor II by α-, β-, and γ-Secretase* , 2007, Journal of Biological Chemistry.

[33]  P. Wong,et al.  Bace1 modulates myelination in the central and peripheral nervous system , 2006, Nature Neuroscience.

[34]  Deborah M. Miller,et al.  The Goldman Consensus statement on depression in multiple sclerosis , 2005, Multiple sclerosis.

[35]  N. Larocca,et al.  The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. , 1989, Archives of neurology.

[36]  J. Sun,et al.  BACE1-Deficient Mice Exhibit Alterations in Immune System Pathways , 2016, Molecular Neurobiology.

[37]  H. Hampel,et al.  Increased CSF-BACE1 activity associated with decreased hippocampus volume in Alzheimer's disease. , 2011, Journal of Alzheimer's disease : JAD.